重组人生长激素联合曲普瑞林治疗女童特发性中枢性性早熟的临床效果  

Efficacy of recombinant human growth hormone combined with triptorelin in the treatment of idiopathic central precocious puberty in girls

作　　者：王祯 田宇波 彭梦竹 Wang Zhen;Tian Yubo;Peng Mengzhu(Department of Child Health Care,Zhumadian Central Hospital,Zhumadian 463000,China)

机构地区：[1]驻马店市中心医院儿童保健科,驻马店463000

出　　处：《中国实用医刊》2023年第14期102-105,共4页Chinese Journal of Practical Medicine

摘　　要：目的探讨重组人生长激素联合曲普瑞林治疗女童特发性中枢性性早熟的临床效果。方法抽取2019年11月至2022年8月驻马店市中心医院收治的特发性中枢性性早熟女童80例,按随机数字表法分为对照组与研究组,每组40例。对照组采用曲普瑞林治疗,研究组采用重组人生长激素联合曲普瑞林治疗。比较两组临床疗效、性激素水平[促卵泡生成素(FSH)、促黄体生成素(LH)水平]、血清胰岛素样生长因子-1(IGF-1)、胰岛素样生长因子结合蛋白-3(IGFBP-3)水平及不良反应发生率。结果研究组临床总有效率(92.50%,37/40)高于对照组(72.50%,29/40),P<0.05。治疗后,研究组FSH、LH水平低于对照组(P<0.05),IGF-1、IGFBP-3水平高于对照组(P<0.05)。研究组不良反应发生率(5.00%,2/40)与对照组(7.50%,3/40)比较差异未见统计学意义(P>0.05)。结论重组人生长激素联合曲普瑞林治疗特发性中枢性性早熟女童,可调节性激素水平和胰岛素敏感性,提高临床效果,并具有用药安全性。Objective To investigate the clinical effect of recombinant human growth hormone combined with triptorelin in the treatment of idiopathic central precocious puberty in girls.Methods A total of 80 girls with idiopathic central precocious puberty treated in Zhumadian Central Hospital from November 2019 to August 2022 were selected,and they were divided into control group and study group according to random number table method,with 40 cases in each group.The control group was treated with triptorelin,and the study group was treated with recombinant human growth hormone combined with triptorelin.The clinical efficacy,levels of sex hormones,including follicle stimulating hormone(FSH)and luteinizing hormone(LH),level of serum insulin-like growth factor-1(IGF-1),level of insulin-like growth factor binding protein-3(IGFBP-3),and incidence of adverse reactions were compared between the two groups.Results The total effective rate in the study group was 92.50%(37/40),which was higher than the 72.50%(29/40)in the control group(P<0.05).After treatment,the levels of FSH and LH in the study group were lower than those in the control group(P<0.05);the levels of IGF-1 and IGFBP-3 in the study group were higher than those in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the study group(5.00%,2/40)and the control group(7.50%,3/40),P>0.05.Conclusions Recombinant human growth hormone combined with triptorelin,in the treatment of idiopathic central precocious puberty in girls,can regulate the level of sex hormones and insulin sensitivity,and improve the clinical effect,with drug safety.

关 键 词：性早熟 女童 重组人生长激素 曲普瑞林 

分 类 号：R725.8[医药卫生—儿科]